This study investigated the bacterial colonization in patients admitted for treatment of drug-resistant tuberculosis in a specialized TB hospital. Identification and antimicrobial susceptibility testing of bacterial isolates (n = 62) from nasal, groin, and rectal swabs [patient cohort (n = 37)] were determined by the VITEK-MS system. Resistance gene analysis was by PCR and DNA sequencing. Molecular typing of Klebsiella pneumoniae isolates was by Multilocus Sequencing Typing (MLST). Patients (n = 13/37; 35%) were colonized by multidrug-resistant (MDR) bacteria (ESBL and MRSA) on admission. Of the 24 patients who were not colonized by MDR bacteria on admission, 46% (17/37) became colonized by MDR bacteria within 1 month of admission, mostly with ESBL-producing Enterobacteriales and resistance to aminoglycosides and fluoroquinolones. ESBL Escherichia coli (41/62; 66%) and K. pneumoniae (14/62; 23%) predominated. Genes encoding for ESBLs (blaCTX-M-14, blaCTX-M-15, blaSHV-28, blaOXA-1, and blaOXY-2) and plasmid-mediated quinolone resistant genes (qnrB1, qnrB4, and qnrB10) were detected. MLST revealed genetic diversity among the K. pneumoniae isolates from hospitalized patients. This study provides insight into bacterial pathogen colonization in hospitalized TB patients with the first occurrence of the qnrB4 and qnrB10 genes and co-expression of genes: qnrB4+aac(6′)-lb-cr, qnrB10+aac(6′)-lb-cr, qnrB4+qnrS1, and qnrB10+qnrS1 in fluoroquinolone-resistant E. coli isolates within South Africa. However, the source and colonization routes of these isolates could not be determined.
Get full access to this article
View all access options for this article.
References
1.
McQuoid-MasonD.2012. Hospital-acquired infections - when are hospitals legally liable? S. Afr. Med. J. 102:353–354.
2.
BrinkA., FeldmanC., DuseA., GopalanD., MerM., NaickerS., PagetG., PerovicO., and RichardsG.. 2006. Guideline for the managment of nosocomial infections in South Africa. SA. J. Epidemiol. Infect. 21:152–160.
3.
DramowskiA., CottonM., and WhitelawA.. 2017. Surveillance of healthcare-associated infection in hospitalised South African children: which method performs best? S. Afr. Med. J. 107:56–63.
4.
GolkarZ., BagazraO., and PaceD.. 2014. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J. Infect. Dev. Ctries. 8:129–136.
5.
VentolaC.2015. The antibiotic resistance crisis. Pharm. Ther. 40:277–283.
6.
BushK., and JacobyG.. 2010. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54:969–976.
7.
DhillonR., and ClarkJ.. 2011. ESBLs: a clear and present danger? Critic. Care Res. Pract. 20:1–11.
8.
CantonR., and CoqueT. M.. 2006. The CTX-M β-lactamase pandemic. Curr. Opin. Microbiol. 9:466–475.
9.
CantonR., GonzalezJ., and GalanJ.. 2012. CTX-M enzymes: origin and diffusion. Front. Microbiol. 3:1–19.
10.
BonnetR.2004. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1–14.
11.
CattoirV., and NordmannP.. 2009. Plasmid-mediated quinolone resistance in Gram-negative bacterial species: an update. Curr. Med. Chem. 16:1028–1046.
12.
CavacoL.M., HasmanH., XiaS., and AarestrupF.M.. 2009. qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. Antimicrob. Agents Chemother. 53:603–608.
13.
Nordmann, Nordmann, P. 2013. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med. Mal. Infect. 44:51–56.
14.
BrinkA., CoetzeeJ., ClayC., CorcoranC., van GreuneJ., DeetlefsJ., NuttL., FeldmanC., RichardsG., NordmannP., and PoirelL.. 2012. The spread of carbapenem-resistant Enterobacteriales in South Africa: risk factors for acquisition and prevention. S. Afr. Med. J. 102:1–2.
15.
GquntaK., van WykJ., EkermansP., BamfordC., MoodleyC., and GovenderS.. 2015. First report of IMI-2 carbapenemase producing Enterobacter clinical isolate in South Africa. SA. J. Infect. Dis. 30:34–35.
16.
PerovicO., IsmailH., and Van SchalkwykE.. 2018. Antimicrobial resistance surveillance in the South African public sector. SAJID. 33:118–129.
17.
DiancourtL., PassetV., VerhoefJ., GrimontP., and BrisseS.. 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J. Clin. Microbiol. 43:4178–4182.
18.
Clinical and Laboratory Standards Institute. 2017. CLSI M100 S27:2017—Performance Standards for Antimicrobial Susceptibility Testing. CLSI, Wayne,, USA, 32–39.
19.
PriyadharsiniR., KavithaA., RajanR., MthaviS., and RajeshK.. 2011 Prevalence of blaCTX-M extended-spectrum beta-lactamase gene in Enterobacteriales from critical care patients. J. Lab. Physicians. 3:80–83.
20.
EssackS., HallL., PillayD., McFadyenM., and LivermoreD.. 2001. Complexity and diversity of Klebsiella pneumoniae strains with extendedspectrum β-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob. Agents Chemother. 45:88–95.
21.
PitoutJ., ThomsonK., HansonN., EhrhardtA., MolandE., and SandersC.. 1998. β-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob. Agents Chemother. 42:1350–1354.
22.
EllingtonM., KistlerJ., LivermoreD., and WoodfordN.. 2007. Multiplex PCR for rapid detection of genes encoding acquired metallo-β-lactamases. J. Antimicrob. Chemother. 59:321–322.
23.
NordmannP., NaasT., and PoirelL.. 2011. Global spread of Carbapenemase producing Enterobacteriales. Emerg. Infect. Dis. 17:1791–1798.
24.
PoirelL., PatronA., and NordmannP.. 2012. OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother. 67:1597–1606.
25.
WangM., GuoQ., XuX., WangX., YeX., WuS., HooperD.C, and WangM.. 2009. New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob. Agents Chemother. 53:1892–1897.
JacobsonR., ManesenM., MoodleyC., SmithM., WilliamsS., NicolM., BamfordC.. 2015. Molecular characterisation and epidemiological investigation of an outbreak of blaOXA-181 carbapenemase-producing isolates of Klebsiella pneumoniae in South Africa. S. Afr. Med. J. 105:1030–1035.
28.
StruveC., RoecC., SteggerM., StahlhutS., HansenD., David EngelthalerM., AndersenP., DriebeE., KeimP., and KrogfeltK.. 2015. Mapping the Evolution of Hypervirulent Klebsiella pneumoniae. mBio. 6:1–12.
29.
HeysellS., ShenoiS., CatterickK., ThomasT., and FriedlandG.. 2011. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage among hospitalised patients with tuberculosis in rural KwaZulu-Natal. S. Afr. Med. J. 101:332–334.
30.
MarchaimD., PogueJ., TzumanO., HayakawaK., LephartP., SalimniaH., PainterT., ZervosM., JohnsonL., PerriM., HartmanP., ThyagarajanR., MajorS., GoodellM., FakihM., WasherL., NewtonD., MalaniA., WholehanJ., ModyL., and KayeaK.. 2015. Major Variation in MICs of Tigecycline in Gram-Negative Bacilli as a Function of Testing Method. J. Clin. Microbiol. 52:1617–1621.
31.
FevreC., JbelM., PassetV., WeillF., GrimontP., and BrisseS.. 2005. Six Groups of the OXY β-lactamase evolved over millions of years in Klebsiella oxytoca. Antimicrob. Agents Chemother. 49:3453–3462.
32.
PatersonD., HujerK., HujerA., YeiserB., BonomoM., RiceL., BonomoR., and the International Klebsiella Study Group. 2003. Extended-spectrum β-lactamases in Klebsiella pneumoniae Bloodstream Isolates from Seven Countries: dominance and Widespread Prevalence of SHV- and CTX-M-Type β-Lactamases. Antimicrob. Agents Chemother. 47:3554–3560.
33.
EssackS., HallL., and LivermoreD.. 2004. Klebsiella pneumoniae isolate from South Africa with multiple TEM, SHV and AmpC β-lactamases. Int. J. Antimicrob. Agents. 23:398–400.
34.
PeiranoG., C.vanGreune, and PitoutJ.. 2011. Characteristics of infections caused by extended-spectrum β-lactamase–producing Escherichia coli from community hospitals in South Africa. Diag Microbiol. Infect. Dis. 69:449–453.
35.
KabaM., ManenzheR., MoodleyC., ZarH., and NicolM.. 2016. Epidemiology of extended-spectrum beta-lactamase- and carbapenemase-producing bacteria in stool from apparently healthy children, South Africa. Int. J. Infect. Dis. 45:96.
36.
De FrancescoA., TanihN., SamieA., GuerrantR., and BessongP.. 2017. Antibiotic resistance patterns and beta-lactamase identification in Escherichia coli isolated from young children in rural Limpopo Province, South Africa: the MAL-ED cohort. S. Afr. Med. J. 107:205–214.
37.
NdugulileF., JureenR., HarthugS., UrassaW., and LangelandN.. 2005. Extended Spectrum β-Lactamases among Gram-negative bacteria of nosocomial origin from an Intensive Care Unit of a tertiary health facility in Tanzania. BMC Infect. Dis. 5:1–6.
38.
MoussoundaM., DieneS., Dos SantosS., GoudeauA., FrançoisP., and van der Mee-MarquetN.. 2017. Emergence of blaNDM-7–producing Enterobacteriales in Gabon, 2016. Emerg. Infect Dis. 23:356–358.
39.
GquntaK., and GovenderS.. 2015. Characterization of ESBL-producing Escherichia coli ST131 isolates from Port Elizabeth. Diag. Microbiol. Infect. Dis. 81:44–46.
40.
ShaoY., XiongZ., LiX., HuL., ShenJ., LiT., HuF., and SChen. 2011. Prevalence of plasmid-mediated quinolone resistance determinants in Citrobacter freundii isolates from Anhui province, PR China. J. Med. Microbiol. 60:1801–1805.
41.
Pérez-MorenoM.O., EstepaV., SáenzY., Cortell-OrtoláM., Fort-GallifaI., RuizJ., and TorresC.. 2012. Intrahospitalary dissemination of Klebsiella pneumoniae carrying blaDHA-1and qnrB4 genes within a novel complex class 1 integron. Diag. Microbiol. Infect. Dis. 73:210–211.
42.
CattoirV., PoirelL., and NordmannP.. 2007. Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant. Antimicrob. Agents Chemother. 51:2652–2653.
43.
LinD., ChenK., Wai-Chi ChanE., and ChenS.. 2015. Increasing prevalence of ciprofloxacin-resistant food-borne Salmonella strains harboring multiple PMQR elements but not target gene mutations. Sci. Rep. 5:1–8.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
